Shanghai Huaota Biopharmaceutical Co., Ltd.
Clinical trials sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd., explained in plain language.
-
New lung cancer drug enters final testing phase
Disease control Not yet recruitingThis study aims to see if a new drug called HB0025 works better than an existing drug called tislelizumab when each is combined with standard chemotherapy. It is for adults with advanced non-squamous non-small cell lung cancer that cannot be surgically removed. About 500 particip…
Phase: PHASE3 • Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New Two-Target antibody enters human testing for stubborn acne
Disease control Not yet recruitingThis early-stage study is testing a new drug called HB0043 for adults with moderate to severe acne. The drug is a special antibody designed to target two specific inflammation pathways thought to drive acne. Researchers will check if the treatment is safe and if it reduces the nu…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New drug trial aims to outperform standard lung cancer treatment
Disease control Not yet recruitingThis study is testing if a new drug, HB0025, works better than the current standard drug, pembrolizumab, when each is given with chemotherapy. It is for adults with advanced or metastatic squamous non-small cell lung cancer who have not had prior treatment. About 480 participants…
Phase: PHASE3 • Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC